PURASORB PLD 9620 is a medical-grade L/D-lactide copolymer supplied as a semicrystalline bioresorbable resin for downstream device fabrication. The application scenarios below are limited to documented device categories in which L/D-lactide copolymers are employed as the primary absorbable matrix. Each scenario identifies the governing quality system, polymer addition range, conversion process, and terminal device format. Where published data for this specific resin configuration is limited, that limitation is stated explicitly and the relevant batch-level characterisation path is given.

Absorbable Fracture Fixation Implants Processed by Medical-Grade Injection Moulding

Formulation of PLD 9620 for load-bearing absorbable osteosynthesis components proceeds with the copolymer as the continuous phase at 70–100 wt%; when osteoconductive fillers such as β-tricalcium phosphate are incorporated, the filler fraction is held at 10–30 wt% to avoid melt viscosity excursions that exceed 1,200 Pa·s at 1 s⁻¹. Pre-drying at 80–100 °C under vacuum or desiccant air with a dew point below -40 °C for 8–16 h is required because residual moisture above 100 ppm accelerates hydrolytic chain scission at the injection unit. Do not compound with amine-functionalised stabilisers, because residual tertiary amines catalyse ester aminolysis and shift the degradation onset earlier than the design specification. In production-scale all-electric injection moulding machines with clamping force between 40 t and 100 t, barrel zones are profiled from 160 °C at the feed throat to 180–195 °C at the nozzle; temperature variation across the barrel must not exceed ±5 °C, otherwise melt viscosity shifts reduce shot-to-shot mass consistency. Cycle time, shear heating, and hot-runner residence time are controlled within narrow limits because prolonged residence above 200 °C induces random transesterification and a measurable reduction in intrinsic viscosity. Mould temperature is maintained at 20–40 °C to balance crystallisation rate and part ejection stability. Compliance for this device family is anchored to ISO 13485:2016, ISO 13781:2017 for poly(lactide) degradation testing, ASTM F2502-17 for bioabsorbable plates and screws, and ISO 10993-5:2009 for cytotoxicity. Tensile and flexural properties are measured according to ISO 527-1:2019 and ISO 178:2019. The terminal device configurations produced from this route include interference screws, suture anchors, craniofacial plates, and osteochondral pins.

Why Does Coating Thickness Influence Drug-Eluting Layer Integrity in Combination Devices?

Drug-eluting implant coatings based on PLD 9620 are applied from single-phase organic solutions in which the polymer-to-active pharmaceutical ingredient ratio is constrained between 50:50 w/w and 95:5 w/w; higher polymer fractions reduce elution rate but increase the risk of acute delamination when coating dry thickness exceeds 8–12 μm on metallic stent platforms. The coating solution is prepared at 3–7% w/v in ethyl acetate or dichloromethane and filtered through a 0.2 μm membrane prior to ultrasonic spray coating. Production-scale coating is performed with an ultrasonic nozzle operating at 0.5–2.0 mL/h flow, 1.5–3.0 W ultrasonic power, and a drying air temperature of 35–45 °C; these parameters control the solvent evaporation front and prevent collapse of the forming polymer skin. Residual solvent limits are governed by ICH Q3C and ISO/TS 10993-17:2023 toxicological risk assessment. The combination product is evaluated under ISO 10993-4:2017 for hemocompatibility, ISO 10993-5:2009 for cytotoxicity, and ISO 10993-6:2016 for local implantation response. Terminal finished product types include drug-eluting coronary or peripheral stent coatings, absorbable coatings on orthopaedic pins, and antimicrobial-eluting surgical mesh coatings. Published data for PLD 9620-specific in vivo elution kinetics in this configuration is limited; batch-level dissolution profiles should be generated under accelerated release conditions at 37 °C in phosphate buffered saline.

Monofilament extrusion of PLD 9620 for absorbable wound closure devices begins with pellet drying to a residual moisture specification below 100 ppm; failure to maintain this level produces voiding and filament diameter variability across the spool. The resin is processed as the 100 wt% matrix; colourants or spin aids are limited to 0.05–0.15 wt% because insoluble particulate above this level increases monofilament break frequency at drawing. The polymer melt is processed in a single-screw extruder with a 30:1 L/D ratio and a metering-section compression ratio of 2.5:1, with barrel temperatures rising from 160 °C to 190–205 °C. A melt pump is placed before the spinneret to damp pressure oscillations to ±1.0 bar; spinneret holes of 0.4–0.8 mm diameter feed a water quench bath controlled at 25–35 °C. Two-stage hot drawing is carried out at 55–70 °C and 70–85 °C with a total draw ratio of 4:1 to 6:1, followed by annealing under nitrogen at 90–110 °C for 6–12 h to reduce free shrinkage. The fibre is cut, oriented, and packaged under ISO 11607-1:2019 sterile barrier requirements. Mechanical acceptance is based on USP <40> suture tensile strength and ISO 10993-6:2016 implantation testing. Terminal product forms include monofilament absorbable sutures, orthodontic ligatures, and small-calibre tissue support fibres.

Solvent-Driven Electrospinning Parameters for Resorbable Craniofacial Barrier Membranes

Barrier membranes for guided bone regeneration are produced from PLD 9620 by solution electrospinning from binary solvent systems of chloroform and dimethylformamide at volume ratios between 80:20 and 70:30; polymer concentration is held at 8–15% w/v to maintain chain entanglement while avoiding bead defects. A continuous positive-displacement syringe pump feeds the solution at 0.5–1.5 mL/h through a 22–27 G blunt needle, with applied voltage of 18–25 kV and a collector distance of 12–18 cm. The resulting fibre mats are post-treated under vacuum at 35–40 °C for 24–48 h to remove residual solvent below ICH Q3C limits. Compliance for the membrane configuration is controlled under ISO 13485:2016 and evaluated by ISO 10993-5:2009, ISO 10993-10:2021 for sensitisation, and ISO 10993-14:2001 for degradation product identification. Membrane formats produced through this route include resorbable dental barrier membranes, sinus lift membranes, and periodontal regeneration matrices.

Fused-filament fabrication of patient-matched resorbable scaffolds uses PLD 9620 filament extruded to a diameter of 1.75 ± 0.05 mm; the filament is predried in a vacuum oven at 60–80 °C for 12–24 h before printing to prevent hydrolytic degradation at the hot end. The polyester is printed as the 100 wt% matrix; when bulk osteoconductivity is required, β-TCP is pre-compounded at 10–20 wt% and the resulting filament is rerouted through a hardened nozzle to limit abrasion. Printing is performed with a direct-drive extruder, a nozzle temperature of 180–200 °C, a bed temperature of 50–60 °C, and a layer height of 0.10–0.15 mm; build chamber humidity is kept below 30% RH because ester hydrolysis occurs at the exposed melt strand. Periodic intrinsic viscosity testing after printing is performed according to ISO 1628-1:2021 to detect molecular weight loss above the design limit. Compliance for implantable scaffolds includes ISO 13485:2016, ISO 10993-1:2018, and ISO 10993-6:2016; mechanical testing follows ASTM D638-14 for printed tensile specimens. Terminal product types include patient-specific craniofacial scaffolds, long-bone segmental defect spacers, and osteochondral repair plugs.

When In Situ Forming Implants Require Solvent Phase Inversion Without Toxic Generation

In situ forming implant systems based on PLD 9620 are compounded by dissolving the copolymer at 25–40 wt% in N-methyl-2-pyrrolidone or dimethyl sulfoxide; the active pharmaceutical ingredient or peptide is loaded at 5–20 wt% of total solution mass, with the balance remaining polymer solution. The sterile liquid is filled under nitrogen into single-use syringes using a peristaltic or rotary piston pump with 0.2 μm sterilising filtration, then terminally sealed under ISO 11607-1:2019. Upon injection into an aqueous physiological environment, solvent exchange induces rapid phase inversion; the PLD 9620-rich phase coagulates into a depot with porosity regulated by the solvent:non-solvent exchange rate and polymer concentration. In process development, injectability is quantified through 21 G needle extrusion force at 25 °C, with acceptance below 30 N after 24 h storage. Compliance is established under ISO 10993-3:2014 for genotoxicity, ISO 10993-5:2009 for cytotoxicity, ISO 10993-6:2016 for local implantation, and ICH Q3C for residual solvent. Terminal finished product types include periodontal pocket depots, subcutaneous sustained-release implants, and injectable void-filling drug matrices. Published data for PLD 9620-specific depot coagulation kinetics in the cited solvents is limited; viscosity, syringability, and coagulation rate must be characterised per lot before process freeze.